ProShare Advisors
DFTX

ProShare Advisors’s Definium Therapeutics DFTX Stock Holding History

ProShare Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$970K Buy
20,615
+1,884
+10% +$46.6K ﹤0.01% 814
2026
Q1 		$354K Sell
18,731
-2,808
-13% -$47.7K ﹤0.01% 1253
2025
Q4 		$288K Buy
21,539
+5,947
+38% +$73.6K ﹤0.01% 1483
2025
Q3 		$184K Sell
15,592
-2,676
-15% -$25K ﹤0.01% 1710
2025
Q2 		$119K Sell
18,268
-941
-5% -$6.19K ﹤0.01% 1846
2025
Q1 		$112K Sell
19,209
-6,958
-27% -$49.8K ﹤0.01% 1813
2024
Q4 		$182K Buy
26,167
+12,562
+92% +$86.4K ﹤0.01% 1914
2024
Q3 		$77.4K Buy
+13,605
New +$94.6K ﹤0.01% 1922
2022
Q2 		– Sell
-4,026
Closed -$67K – 1995
2022
Q1 		$67K Sell
4,026
-1,041
-21% -$18.1K ﹤0.01% 2089
2021
Q4 		$105K Buy
5,067
+2,094
+70% +$66.8K ﹤0.01% 2196
2021
Q3 		$104K Sell
2,973
-2,597
-47% -$112K ﹤0.01% 1909
2021
Q2 		$288K Buy
+5,570
New +$292K ﹤0.01% 1923

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ProShare Advisors's DFTX Position: Q2 2026 in Review

ProShare Advisors increased its Definium Therapeutics (DFTX) stake by 10% in Q2 2026, buying an estimated $46.6K and bringing the position to 20,615 shares worth $970K. The position accounts for ﹤0.01% of the portfolio, ranked #814.

ProShare Advisors first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • ProShare Advisors held 20,615 shares of Definium Therapeutics worth $970K as of Q2 2026.
  • ProShare Advisors bought 1,884 Definium Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Definium Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #814 holding.
  • ProShare Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.